标题
Current pharmacotherapy for testicular germ cell cancer
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-14
出版商
Informa UK Limited
发表日期
2019-03-09
DOI
10.1080/14656566.2019.1583745
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
- (2018) Daniela Matei et al. CLINICAL CANCER RESEARCH
- Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors
- (2018) Christoph Seidel et al. EUROPEAN JOURNAL OF CANCER
- Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel
- (2018) Joost L. Boormans et al. EUROPEAN UROLOGY
- Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era
- (2018) Harmke J. Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Molecular Characterization of Testicular Germ Cell Tumors
- (2018) Hui Shen et al. Cell Reports
- The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors
- (2018) Christoph Oing et al. Oncology Research and Treatment
- Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
- (2018) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent global trends in testicular cancer incidence and mortality
- (2018) Jee Soo Park et al. MEDICINE
- Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors
- (2018) Silvia Schmidtova et al. Current Oncology Reports
- Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
- (2018) Richard Cathomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines
- (2017) Stefan Schönberger et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
- (2017) Torgrim Tandstad et al. JOURNAL OF CLINICAL ONCOLOGY
- 111: A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT).
- (2017) Robert Anthony Huddart et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
- (2017) Nabil Adra et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study.
- (2017) Iwona Anna Skoneczna et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
- (2016) T. Tandstad et al. ANNALS OF ONCOLOGY
- Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
- (2016) Andrea Necchi et al. Clinical Genitourinary Cancer
- Investigational targeted therapies for the treatment of testicular germ cell tumors
- (2016) Christoph Oing et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Anxiety and depression in long-term testicular germ cell tumor survivors
- (2016) S. Vehling et al. GENERAL HOSPITAL PSYCHIATRY
- Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
- (2016) Mirjam Gerwing et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Testicular seminoma clinical stage 1: treatment outcome on a routine care level
- (2016) Klaus-Peter Dieckmann et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors
- (2016) Aditya Bagrodia et al. JOURNAL OF CLINICAL ONCOLOGY
- Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group
- (2016) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors
- (2016) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of everolimus in refractory testicular germ cell tumors
- (2016) Michal Mego et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group
- (2016) Christoph Seidel et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
- (2016) Costantine Albany et al. Oncotarget
- Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors
- (2015) H. Boer et al. ANNALS OF ONCOLOGY
- Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors
- (2015) Y. Nieto et al. ANNALS OF ONCOLOGY
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- Frequent PD-L1 expression in testicular germ cell tumors
- (2015) C D Fankhauser et al. BRITISH JOURNAL OF CANCER
- Guidelines on Testicular Cancer: 2015 Update
- (2015) Peter Albers et al. EUROPEAN UROLOGY
- Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments
- (2015) Christoph Oing et al. EXPERT OPINION ON PHARMACOTHERAPY
- Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance
- (2015) Christian Kollmannsberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom burden in long-term germ cell tumor survivors
- (2015) Karin Oechsle et al. SUPPORTIVE CARE IN CANCER
- Late Relapse of Testicular Germ Cell Tumors
- (2015) Matthew J. O’Shaughnessy et al. UROLOGIC CLINICS OF NORTH AMERICA
- Current chemotherapeutic approaches for recurrent or refractory germ cell tumors
- (2015) Brent O׳Carrigan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
- (2014) K. Fizazi et al. ANNALS OF ONCOLOGY
- One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
- (2014) T. Tandstad et al. ANNALS OF ONCOLOGY
- Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
- (2014) J. Oldenburg et al. ANNALS OF ONCOLOGY
- A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program
- (2014) Mette Saksø Mortensen et al. EUROPEAN UROLOGY
- Testicular Cancer: A Reflection on 50 Years of Discovery
- (2014) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort
- (2014) Gedske Daugaard et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma
- (2013) A Horwich et al. BRITISH JOURNAL OF CANCER
- The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
- (2013) M. Juliachs et al. CLINICAL CANCER RESEARCH
- Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes
- (2013) Andrea Necchi et al. Clinical Genitourinary Cancer
- A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study
- (2013) Karim Fizazi et al. EUROPEAN UROLOGY
- A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
- (2013) Darren R. Feldman et al. INVESTIGATIONAL NEW DRUGS
- Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview
- (2013) Paolo Chieffi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
- (2013) Craig R. Nichols et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
- (2012) B Nitzsche et al. BRITISH JOURNAL OF CANCER
- The Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature
- (2012) Fabio Calabrò et al. EUROPEAN UROLOGY
- Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial
- (2012) Anja Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983
- (2012) Ronald de Wit et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition
- (2012) Francesca Cavallo et al. PLoS One
- Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial
- (2012) Darren R. Feldman et al. Journal of Cancer
- Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
- (2011) K. Oechsle et al. ANNALS OF ONCOLOGY
- Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors
- (2011) Karin Oechsle et al. EUROPEAN UROLOGY
- Third-Line Chemotherapy and Novel Agents for Metastatic Germ Cell Tumors
- (2011) Christine M. Veenstra et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
- (2011) Jorge Aparicio et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database
- (2011) Anja Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)
- (2011) R. Timothy D. Oliver et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
- (2010) G. Daugaard et al. ANNALS OF ONCOLOGY
- Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma
- (2010) Hannes Steiner et al. BJU INTERNATIONAL
- TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis
- (2010) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study
- (2010) Hege S. Haugnes et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of good risk germ-cell tumours
- (2009) Monique M. Troost et al. BJU INTERNATIONAL
- Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
- (2009) Darren R. Feldman et al. INVESTIGATIONAL NEW DRUGS
- Microsatellite Instability, Mismatch Repair Deficiency, andBRAFMutation in Treatment-Resistant Germ Cell Tumors
- (2009) Friedemann Honecker et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program
- (2009) Torgrim Tandstad et al. JOURNAL OF CLINICAL ONCOLOGY
- Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy
- (2008) K. Oechsle et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group
- (2008) Peter Albers et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now